Article

Role of biofilms in chronic inflammatory diseases of the upper airways.

Institute of Otorhinolaringology, Catholic University of the Sacred Heart, Rome, Italy.
Advances in Oto-Rhino-Laryngology 01/2011; 72:93-6. DOI: 10.1159/000324622
Source: PubMed

ABSTRACT The objective of our studies was to document the presence of bacterial biofilms in recurrent and chronic infectious diseases of the upper airways (UA) (adenoiditis, tonsillitis, chronic rhinosinusitis) and to assess the association between the presence of biofilm and the maintenance of a chronic inflammation.
16 surgical samples of tonsils and adenoids from patients with UA infections and 24 samples of ethmoid mucosa from patients who underwent endoscopic sinus surgery for chronic rhinosinusitis (CRS) were cultured using conventional methods and subjected to scanning electron microscopy (SEM) to detect evidence of biofilm.
Bacterial biofilms were observed in 57.5% of chronically infected UA mucosa; in 41.7% of ethmoid mucosa of CRS patients they were significantly (p<0.001) associated with a marked destruction of ciliated epithelium.
Our studies confirm that biofilm formation plays a role in UA infections, it not only explains the resistance of these infections to antibiotic therapy, but also represents an important element that contributes to the maintenance of a chronic inflammatory reaction.

0 Followers
 · 
101 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic rhinosinusitis (CRS) affects nearly 37 million people in the United States each year and accounts for approximately $6 billion in direct and indirect health care costs. Despite its prevalence and significant impact, little is known about its exact cause and pathophysiology, and significant controversy remains regarding appropriate treatment options. Basic science research, however, has shown recent promise toward improving understanding of the innate and environmental factors underlying the pathophysiology of CRS. The hope is that this will also lead to advances in treatment for children adversely affected by this common yet complicated disease.
    Pediatric Clinics of North America 08/2013; 60(4):979-91. DOI:10.1016/j.pcl.2013.04.001 · 2.20 Impact Factor